This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Nicox's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.175. Nicox's 10-Year median PS Ratio is 13.2571. Therefore, the Median PS Value for today is €2.32.
As of today (2024-12-12), Nicox's share price is €0.28. Nicox's Median PS Value is €2.32. Therefore, Nicox's Price to Median PS Value for today is 0.12.
The historical rank and industry rank for Nicox's Median PS Value or its related term are showing as below:
LTS:0RCQ'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12 Med: 0.31 Max: 0.43
Current: 0.12
During the past 13 years, the highest Price to Median PS Value of Nicox was 0.43. The lowest was 0.12. And the median was 0.31.
LTS:0RCQ's Price-to-Median-PS-Value is ranked better than 93.56% of 264
companies
in the Biotechnology industry
Industry Median: 0.7
vs LTS:0RCQ: 0.12
Nicox Median PS Value Historical Data
The historical data trend for Nicox's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nicox's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nicox's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nicox's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Nicox's Price-to-Median-PS-Value falls into.
Nicox Median PS Value Calculation
Nicox's Median PS Value for today is calculated as
10-Year Median PS Ratio is 13.2571.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nicox's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.175.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nicox (LTS:0RCQ) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Nicox's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.28
/
2.32
=
0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nicox Median PS Value Related Terms
Thank you for viewing the detailed overview of Nicox's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0RCQ has been successfully added to your 